Start Date
November 30, 2011
Primary Completion Date
June 30, 2014
Study Completion Date
July 31, 2015
RGB-286638
The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks)
Lead Sponsor
Agennix
INDUSTRY